Member Info for Vascular

I wouldn't be surprised if the rest of the rest of the consortium and god knows who else, start taking advantage of this SP weakness as a means of leveraging up their profits once / when the orders start to build.....lol

" Johnson also revealed plans for a programme of mass testing, similar to that which took place as part of a pilot in Liverpool, to be rolled out in all tier-three areas in England after the lockdown ends. Johnson said rapid coronavirus tests are already being deployed in the NHS and in care homes, with the goal of allowing every care home resident to have two visitors who can be tested twice a week by the end of the year."

Read more: https://www.newscientist.com/article/2237475-covid-19-news-uk-on-track-to-start-vaccine-roll-out-in-december/#ixzz6eeDjAq1s

Read more: https://www.newscientist.com/article/2237475-covid-19-news-uk-on-track-to-start-vaccine-roll-out-in-december/#ixzz6eeDVNk00

https://www.newscientist.com/article/2237475-covid-19-news-uk-on-track-to-start-vaccine-roll-out-in-december/

Sorry. here is the RNS

https://www.londonstockexchange.com/news-article/ODX/uk-rtc-update/14758509

"This begs the question what has happened to Ciga and BBI who are also members of the consortium, does the consortium even still exist? We were all aware that the agreement ran out in October so we were expecting an update, but nothing was announced."

MikODX. The consortium still existed when Omega put out this RNS on the 17th November.

Interestingly I heard that no one on the Oxford trial was admitted to hospital for chronic symptoms of covid following taking their vaccine.....which if true, is a brilliant result. This could demonstrate that those who were not protected by vaccine, developed milder symptoms.....

although i did read somewhere that ODX either have a sales team in India, or at least are involved with a sales team...

Didn't they sell it....?

same link as before.....takes you here

https://www.medrxiv.org/content/10.1101/2020.09.29.20201509v2

Found by Korda and deserves its own title.
Laboratory evaluation of SARS-CoV-2 antibodies: detectable IgG up to 20
weeks post infection!
"On the known positive 54 cohort, the UK-RTC AbC-19 lateral flow immunoassay showed a sensitivity of 97.58%
55 (95.28%-98.95%) and on known negatives, showed specificity of 99.59% (98.53 %-
56 99.95%)Through comprehensive analysis of a cohort of pre-pandemic and pandemic
59 individuals, we show detectable levels of IgG antibodies, lasting up to 140 days,
60 providing insight to antibody levels at later time points post infection.

https://www.medrxiv.org/content/10.1101/2020.09.29.20201509v2.full.pdf

Excellent Korda. Thanks.

https://www.sharesmagazine.co.uk/news/market/LSE20201119080002_3785030/Schedule-One-Abingdon-Health-PLC

Does mention friday this week here, if they actually did decide to go forward on this IPO.
and we have been stuck in a holding position for the entire week....
https://news.sky.com/story/covid-antibody-firm-abingdon-health-tests-market-on-100m-float-12133864

How does that work RED? Sounds painful, especially if your the one not expecting it!

Trouble is its been like this ( held back) for what seems like weeks, but probably a week or so...so whatever the reason that this is being held back is, its nothing new? can't see it being linked to the IPO...

I contacted Walbrook earlier this morning and asked several questions mainly about the relationship between the AbC-19 Rapid Test and the Oxford University vaccine. Ill list the main points below form the reply which many of you probably are aware of, but may still be useful to others.
They both target the same antibody response to SARSCoV- 2.
UK-RTC researchers developing the AbC-19 Rapid TestTM had access to the SARS-CoV-2 antigens used by the Oxford research teams, ensuring both the assay and the vaccine target the same antibody response.
The AbC-19 Rapid Test is targeted at IgG antibodies to the full spike protein of SARS-CoV-2 (COVID19) to indicate a measure of immune response (aligned with neutralizing antibodies)
This differs from other antibody tests such as those measuring IgM and IgG to the nucleocapsid
The measurement of IgG to spike is required to understand levels of immunity producing antibodies as generated naturally or via vaccination.
The AbC-19 test however is not the only antibody tests that targets the IgG to spike.
There is no contractual relationship between the role out of the Oxford vaccine and the AbC-19 Rapid test
However, the UK-RTC will certainly be leveraging the connections mentioned above both in their existing supply agreement with the UK Government and with other third parties via their own marketing and commercial promotion.

A few questions to those more knowledgeable than me on this board ...
What other antibody tests are similar to the The AbC-19 test in regards to targetings the IgG to spike. Any names
What advantage, if any ( manufacturing wise / quality wise - not relationship wise) would ODX have considering that they have had access to Oxford SARS-CoV-2 antigens and assays used by the Oxford research teams to target the same antibody response, compared to another company, a competitor that can also target this IgG spike?

Complicated stuff for me, but you get my gist.

Does ODX have a scientific advantage over a another company selling a similar antibody test ( to IgG spike), but did not work with Oxford /. AZ.

any minute now

Phase two
"The ChAdOx1 nCov-2019 vaccine has been shown to trigger a robust immune response in healthy adults aged 56-69 and people over 70.

Phase two data, published in The Lancet, suggests one of the groups most vulnerable to serious illness and death from Covid-19 could build immunity, researchers say.

Phase three trials of the vaccine are ongoing, with early efficacy readings possible in the coming weeks.

UK authorities have placed orders for 100 million doses of the vaccine - enough to vaccinate most of the population - should it receive regulatory approval......The study has found the vaccine, being developed with AstraZeneca, was less likely to cause local reactions at the injection site and symptoms on the day of vaccination in older adults than in the younger group.............We were pleased to see that our vaccine was not only well tolerated in older adults, but also stimulated similar immune responses to those seen in younger volunteers."
plus nit can be distributed and administered without specialist freezers etc etc
https://www.telegraph.co.uk/global-health/science-and-disease/coronavirus-news-covid-lockdown-end-pfizer-vaccine-update/

Shame the consortium can't put t put out a general news release of how this news effects them as a consortium .... then ODX could RNS it?

Any luck Oxford results out this week or weekend. I'm not sure what effect this will have on SP but need to be positive and then let people work out the numbers....no way ODX can fill these quantitys alone. Could be tomoz, who knows.GL

Remember ODX have a test aligned with the Oxford / AstraZeneca vaccine then listen to this ......... there is huge hope and optimism that the Oxford vaccine results will be out imminently, they be successful and could be the first vaccine rolled out in the UK = 100 million vaccines on order already, probably need twice as may tests.
https://www.youtube.com/watch?v=ryZIcQFAzhM&ab_channel=CNA